Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Lowers Price Target to $79
Portfolio Pulse from richadhand@benzinga.com
Raymond James analyst Steven Seedhouse has maintained a 'Strong Buy' rating on Mirum Pharmaceuticals (NASDAQ:MIRM), but lowered the price target from $82 to $79.

August 04, 2023 | 3:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mirum Pharmaceuticals' price target has been lowered from $82 to $79 by Raymond James, though the 'Strong Buy' rating is maintained.
The lowering of the price target might indicate a slightly less optimistic outlook for the company's stock. However, the maintenance of the 'Strong Buy' rating suggests that the analyst still sees significant upside potential. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100